Predictors of fulvestrant long-term benefit in hormone receptor-positive/HER2 negative advanced breast cancer

Predictors of fulvestrant long-term benefit in hormone receptor-positive/HER2 negative advanced breast cancer

Abstract We retrospectively investigated in women treated with fulvestrant for HR+/HER2 negative advanced breast cancer clinical, pathological and molecular features associated with long-term benefit from treatment defined as being progression-free at 18 months. Specifically, we analyzed on formalin...

Full description

Bibliographic Details
Main Authors: Rosalba Torrisi, Valentina Vaira, Laura Giordano, Annarita Destro, Vera Basilico, Saveria Mazzara, Piermario Salvini, Gabriella Gaudioso, Bethania Fernandes, Noemi Rudini, Giovanna Masci, Armando Santoro
Format: Article
Language:English
Published: Nature Portfolio 2022-07-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-16409-7

Internet

https://doi.org/10.1038/s41598-022-16409-7

Similar Items